Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Got mine this morning.
I agree we could do with some sort of update.
Some buying over at NXPL, maybe we hear something soon.
I would hope to see some sort of PR or filing today confirming this.
No worries, it’s all very confusing.
Biotech investing is certainly not for the faint hearted. There is no reason for the sudden drop, other than it went up very quickly. There has been no bad news, in fact news has been pretty good. Cash on hand is at or near market cap and it looks like we have a very good liver drug.
The drop sucks as we got so close to going and staying above $1, but some have just been given the chance to buy at a 50% reduction, I know I doubled my holding.
Most recent 8K;
On January 5, 2023, the Board fixed the date on which the Dividend shall be paid to be January 19, 2023 (the “Payment Date”), such Payment Date being within 60 days following the Record Date.
The Dividend Stock will be subject to certain transfer restrictions through May 11, 2023. Payment of the Dividend is conditioned upon the Board not revoking the dividend prior to the Payment Date.
Scotiaitrade, that what I used
I was just able to buy, maybe it’s because I am up in Canada
Serb you had any issues with the RXMDD board today. I can’t even get onto it, says it’s no longer recognized.
I think everyone is waiting for news.
Any news as and when it comes,this is coiled so tight as a result of min shares available it will pop big.
Shareholder letter;
Tampa, FL, January 6, 2023 — McapMediaWire — RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients, today provides a corporate update and letter to shareholders from CEO Tom Wood.
Dear RemSleep Shareholders,
2023 is shaping up to be an extremely pivotal year for RemSleep and I couldn’t be more excited for the Company due to how we are currently positioned going into the New Year. We have several key priorities, goals, and product updates that I’d like to share with our investors as we look out into the next six months.
Our first and primary goal is a successful 510K submission for the DeltaWave CPAP mask. As stated in previous press releases, we hired an extremely qualified Senior Director for Regulatory Compliance and Regulatory Submission in Judy Strzepek. Her prior experience, collaboration with our new testing partner (who specializes in respiratory class II medical device testing, cleaning, and validation), and expertise with the FDA procedures has already proven to be invaluable to the submission process. We successfully completed a key meeting with the FDA last month which reaffirmed our testing criteria, testing execution, and remaining testing plan going forward. DeltaWave testing remains on track and is expected to be completed by mid-February to mid-March. Upon completion, we plan on immediately submitting our finalized FDA 510k submission. On a separate but related note, we are excited to announce our next generation masks, servicing both consumer and institutional (hospital, clinics, nursing homes, etc.) markets, could be on the market much sooner than originally anticipated due to the regulatory guidance provided by Ms. Strzepek. Once the current version of DeltaWave is cleared by the FDA, RemSleep will now have a quicker pathway to clearance for subsequent generations of DeltaWave based on their functionality or changes made to the original version. This will result in saving the company significant time and money in the clearance process as well as getting these products to market.
In conjunction with our confidence in the 510K process, the company is ramping up its sales and marketing plan for the release of the patented DeltaWave mask and next generation masks. This plan includes: adding additional in house and 3rd party resources to further develop this plan and launch these products; evaluating and further developing existing distributor and industry partners for a successful, commercial launch; naming of the new, next generation products, as well as some yet to be announced products, so all remain consistent with the RemSleep branding; and finally, adding professional sales executives with product launch & industry experience. Prioritizing this plan in the first quarter will help ensure a successful, broad market launch of the DeltaWave and next generation products upon FDA clearance.
Business execution continues to be a constant priority. The Company remains in a healthy cash position and expects to have sufficient capital on hand to execute the business plan through the successful commercial launch of the aforementioned products. Please see our latest financial statements as filed with OTC Markets Group. Within the business execution realm, we have reassessed the CPAP inventory and initial sales plan and have pursued new sales channels to address this inventory and future sales. The CPAP industry had several key product recalls in a rather difficult time period where supply was already short and demand was soaring. While this created opportunity for immediate sales and exposure, it also created new concerns and hesitation for distributors and end users with respect to liability. We had a key customer, who represented a substantial volume of initial pre-sales for these CPAP machines, back out of an agreement as they waited for clarity from the industry concerning new approvals and regulations in light of the ongoing and/or developing recalls. The presold units thus became unexpected inventory. While a number of these units were subsequently sold to different customers, we carried significantly more inventory than planned and thus had to shift focus on new markets for these particular units. This issue is not unique to RemSleep and remains an ongoing, industry challenge. That being said, that shift in focus has created a new sales channel development and has restored our confidence in these CPAP sales. While it is too soon to formally announce this development, we will share it with investors as soon as it is prudent to do so from a regulatory and competitive, strategic standpoint. Besides the revenue impact for the Company, this shift of product out of inventory on the balance sheet will free up significant capital for the ongoing business execution through and past FDA clearance.
Finally, our next generation masks have shown strong, internal indications of relief from those suffering from Chronic Obstructive Pulmonary Disease (COPD) and/or Congestive Heart Failure (CHF) in conjunction with their sleep apnea. We plan to conduct formal, FDA clinical study/trials to prove efficacy of this relief from COPD and CHF. Currently, there are no sleep apnea/CPAP masks on the market with these multiple indications. Successful, clinical trials should give RemSleep a competitive advantage for a new market for traditional CPAP masks. Further, it will be a critical step in differentiating the superiority of RemSleep products in the marketplace and subsequently further the sales, marketability, and overall profitability of the RemSleep product lineup. From the beginning, the Company has had a goal of being acquired. This new market should dramatically enhance the overall value of RemSleep and sense of urgency to act for potential acquirers. We are currently evaluating potential hospitals and sleep centers for these future studies/trials.
We have come a long way through our successes and setbacks but we still have a lot of work to do. However, our path is clear and we will continue to focus on the business execution from here on out. There are additional goals and targets for the Company longer term, but let’s get through the FDA 510K process first and allow that clearance to continue to open doors for the Company. We continue to appreciate and value the input, patience, and loyalty from our shareholders. We have the right team in place, with the right products coming to the market at the right time, and a wonderful investor base. For those reasons, I am truly thankful and excited for this New Year. Now let’s get back to work!
I think we will see this, but I expect it to be part of a further cash injection. Lots going on behind the scenes I think.
Just imagine what this will do when we get news.
No it’s the following Monday, on the 16th Martin Luther King Day
Well it’s certainly been a learning experience. I would not say broke as I sold enough on the run to $30 to cover my initial investment and some. I left a lot on the table and could have been set up nicely if I had sold all.
I have made some up on other stocks and one thing I learned was to spread the money around and not be over invested in 1 stock.
Big question is what do they plan to do with the money, I think we will find out very soon.
Stock,
I posted a few days ago, that without the RS there really was no way for management and associates to invest in RXMD, if RXMD needed more cash for some sort of investment. Do you agree with this?
If RXMD has something brewing that needed more cash, they certainly have a way to fund it now.
Just filed;
On November 03, 2022, the registrant (the” Investment Manager”), signed a Financial Management Agreement/Contract (the “Agreement”) with an international ultra-high-net-worth investor group (the “Investor Party”) to manage an investment amount (the “Investment Amount”) of One Billion United States Dollars (USD 1,000,000,000) on behalf of the Investor Party for investment in select transactions and projects to be selected, advised and managed by the Investment Manager for a period of ten years. According to the Agreement, the Investment Manager shall be entitled to 15% of the Investment Amount for its own investment and benefits. In addition, the sharing of profits and dividends from the investment results of 80% of the Investment Amount will be determined by the two parties in a subsequent agreement.
And that post would indicate that he has not sold any shares. He knows the plan and is still a shareholder.
Has Armen gone?
If I could I would have added at these levels, maybe tomorrow it will sort itself out so I can trade.
Good on you, still can’t trade at the moment.
I need my account to allow me to buy, if you can I would add now, I know I would.
Can’t add them on mine at the moment my order was instantly rejected
I would not be surprised to see insiders and associates purchase more shares in RXMD in order to expand. There was no way for them to invest more money in the company and get shares, now they can if they have targets for expansion.
We should hear something from the company soon as to what is going on.
That Div is going up, look at SCLX shares this morning.
Just a thought;
We have seen that our new CEO who is very wealthy is willing to invest his own money. Recently he took with others a big stake in RXMD and also recently purchased more shares in NXPL. With the way the previous share structure worked he would not have really been able to buy more shares in order that RXMD could add more money to its cash pile. Now if there is something big happening which requires our CEO and others to invest more cash, then RXMD now has the shares in place to sell to the CEO to raise such cash.
Our CEO and friends are not afraid to spend and as we have seen they will not undercut the market, I mean they just paid $1.75 for more shares in NXPL which was above market price.
I think over the next month we will see what is planned.
Ok thanks
Any idea how long it will take before RXMDD will trade.
And also Iliad is long gone as you know, and so many other companies have had their share price drastically reduced over the past few months during this decline and one of the worst tax loss selling seasons we have seen for years, it’s not just an RXMD or NXPL issue.
I think you will find they did donate turkeys during thanksgiving
Tomorrow is final day for tax loss selling
Yes and they can move the price up when they want to.
And up again this morning.
Exactly what is happening to NXPL share price today.
I was thinking the same thing myself. I honestly believe that both companies will merge and by doing this there will be significant cost saving for both. We have already seen some of these savings, we have a CEO that does not take a salary and a CFO that works for both companies. Merge and we probably reduce manpower and also head office costs, and also listing costs for both exchanges.
Maybe you forgot about this;
Specifically, as previously disclosed, in April 2019, the Company filed an arbitration demand against NantPharma, LLC (“NantPharma”) and its Chief Executive Officer Patrick Soon-Shiong, seeking several hundred million dollars in damages for alleged breaches of the Stock Sale and Purchase Agreement, dated May 14, 2015, entered into between NantPharma and the Company, arising out of NantPharma’s purchase of the drug Cynviloq™ from the Company in May 2015. Sorrento’s claims against NantPharma remain pending before the American Arbitration Association, and have been submitted to the arbitrator for a decision, which is currently expected later this year.
There is probably a lot pending on this outcome which is due any-day now.
Never got this;
Proposal No. 3: To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.